ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025
Integrating plasma p-tau217 and digital cognitive assessments for early detection in Alzheimer's disease.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Digital memory assessments and plasma pTau217 enable efficient preclinical Alzheimer's trials.The journal of prevention of Alzheimer's disease · 2026Trial
- Digital cognitive phenotyping enhances risk stratification in preclinical Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Modernizing cognitive assessment in Alzheimer's disease.Nature aging · 2026Article
- Validation of Plasma p-tau217 as a Biomarker of Prodromal Alzheimer's Disease.Revista de neurologia · 2026Article
- Scalable markers for early cognitive decline: Plasma p-tau217, subjective cognitive concerns, and digital testing: Results from the A4/LEARN studies.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Combining p-tau217 and digital cognitive testing to predict cognitive decline.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Baseline plasma p-tau217/Aβ42 as a sensitive marker for the severity of Alzheimer's disease continuum.Journal of translational medicine · 2026Article
- Profiling Plasma Biomarkers, Particularly pTau217 and pTau217/Aβ42, and Their Relation to Cognition in Memory Clinic Patients.Journal of neurochemistry · 2025Article
- Article
- Integrating plasma p-tau217 and digital cognitive assessments for early detection in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- A scalable workflow using digital cognitive assessment and pTau217 for MCI detection.Alzheimer's & dementia (Amsterdam, Netherlands)Article
- Establishment and verification of reference intervals for Alzheimer's disease plasma biomarkers based on evaluation of pre-analytical procedures: a multicenter study.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
- Update of
Authors and funding
2 authors.
Funding
Abstract
introductionPlasma phosphorylated tau (p-tau)217 is an early Alzheimer's disease (AD) biomarker, but the timing of pathological changes and cognitive decline varies substantially. Digital cognitive assessments can detect subtle cognitive changes, suggesting they may complement p-tau217 for early detection. Here, we evaluate whether combining these tools improves the detection of individuals at risk for future decline.
methodsWe analyzed 954 amyloid-positive cognitively unimpaired individuals who completed a digital cognitive assessment and a blood test for p-tau217, assessing their ability to predict future decline on the Preclinical Alzheimer Cognitive Composite (PACC) and Mini-Mental State Examination (MMSE).
resultsCombining performance on a digital cognitive assessment with p-tau217 improved identification of individuals who declined on the PACC and MMSE in the next 5 years. The predictive value was stronger in apolipoprotein E ε4 noncarriers but did not differ by sex. DISCUSSION: This approach offers a sensitive method for identifying individuals at high risk for AD-related cognitive decline. HIGHLIGHTS: Combining plasma phosphorylated tau 217 with baseline digital cognitive assessment improved the prediction of cognitive decline on gold-standard neuropsychological tests over the next 5 years, achieving greater accuracy than either measure alone. This combination also predicted a decline in a global cognitive screening test. Pairing a blood test with a digital cognitive assessment offers a scalable and feasible approach for Alzheimer's disease screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.